fasudil has been researched along with Coronary Artery Disease in 11 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Investigations from basic biology suggest that activation of the Rho/Rho kinase pathway reduces the bioavailability of nitric oxide (NO) and thereby promotes atherosclerosis and its clinical complications." | 2.72 | Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. ( Creager, MA; Ganz, P; Grunert, ME; Liao, JK; Nohria, A; Noma, K; Prsic, A; Rikitake, Y, 2006) |
| "Fasudil is a ROCKs inhibitor which has potential benefits in coronary artery spasm and myocardial ischemia." | 2.45 | Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. ( Dong, M; Yan, BP; Yu, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, Z | 1 |
| Qiu, B | 1 |
| Wang, Q | 2 |
| Wei, W | 1 |
| Huang, J | 1 |
| Duan, W | 1 |
| Miyahara, S | 1 |
| Jenke, A | 1 |
| Yazdanyar, M | 1 |
| Kistner, J | 1 |
| Immohr, MB | 1 |
| Sugimura, Y | 1 |
| Aubin, H | 1 |
| Kamiya, H | 1 |
| Okita, Y | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Suda, A | 1 |
| Takahashi, J | 1 |
| Hao, K | 1 |
| Kikuchi, Y | 1 |
| Shindo, T | 1 |
| Ikeda, S | 1 |
| Sato, K | 1 |
| Sugisawa, J | 1 |
| Matsumoto, Y | 1 |
| Miyata, S | 1 |
| Sakata, Y | 1 |
| Shimokawa, H | 3 |
| Fang, J | 1 |
| Cai, C | 1 |
| Chai, Y | 1 |
| Zhou, J | 1 |
| Huang, Y | 1 |
| Gao, L | 1 |
| Cheng, F | 1 |
| Dong, M | 1 |
| Yan, BP | 1 |
| Yu, CM | 1 |
| Ding, R | 1 |
| Hu, DY | 1 |
| Xia, K | 1 |
| Yang, XC | 1 |
| Seto, M | 1 |
| Asano, T | 1 |
| Surma, M | 1 |
| Wei, L | 1 |
| Shi, J | 1 |
| Hoka, S | 1 |
| Hattori, T | 1 |
| Higashi, M | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
| Nohria, A | 1 |
| Grunert, ME | 1 |
| Rikitake, Y | 1 |
| Noma, K | 1 |
| Prsic, A | 1 |
| Ganz, P | 1 |
| Liao, JK | 1 |
| Creager, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fasudil and Coronary Artery Disease
| Article | Year |
|---|---|
Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Coronary Artery Disease; Coronary Vasospasm; Humans; | 2009 |
[Rho-kinase inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Clinical Trials as Topic; Coronary A | 2011 |
Rho kinase as a therapeutic target in cardiovascular disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Apoptosis; Cardiovascular Diseases; Coronary | 2011 |
[Basic and clinical studies on coronary vasospasm].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Coronary Artery Disease; Co | 2002 |
1 trial available for fasudil and Coronary Artery Disease
| Article | Year |
|---|---|
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Brachial Artery; Coronary Artery Disease; Cross | 2006 |
6 other studies available for fasudil and Coronary Artery Disease
| Article | Year |
|---|---|
Fasudil on Myocardial Injury in Rats with Myocardial Ischemia and Reperfusion through Rho-ROCK Signal Pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Ischemia; M | 2022 |
The combination approach with Rhokinase inhibition and mechanical circulatory support in myocardial ischemia-reperfusion injury: Rho-kinase inhibition and ventricular unloading.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Artery Disease; Humans; Male; Myoca | 2022 |
Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Coronary Angiography; Coronary | 2019 |
Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Biological Products; Coronary Artery Disease; Dexamet | 2019 |
Increased RhoA/ROK mRNA expression and function in diabetic vein grafts compared with nondiabetic vein grafts and diabetic arterial grafts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Case-Control Studies; Coronary Artery By | 2010 |
Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenoviridae; Animals; Cell Movement; Coronary Artery | 2004 |